Carboplatin + epirubicin + VP-16 + lenograstim followed by radiotherapy + carboplatin as radiosensitizer in limited small cell lung cancer. A multicenter phase II study

Cesare Gridelli, Carlo Curcio, Rosario Vincenzo Iaffaioli, Luigi Brancaccio, Modesto D'Aprile, Vittorio Gebbia, Antonio Rossi, Anna Tortoriello, Enzo Veltri, Paolo Maione, Alfonso Barbarisi, Ciro Gallo, Cesare Guida, Francesco Perrone

Research output: Contribution to journalArticle

Abstract

A phase II trial was undertaken to test the activity and toxicity of carboplatin (300 mg/m2, i.v. day 1) + epirubicin (75 mg/m2, i.v. day 1) + VP-16 (100 mg/m2, i.v. days 1 to 3) + lenograstim (5 mcg/kg, s.c. days 6 to 15) administered every 3 weeks for 4 cycles and subsequent chest irradiation (50 Gy) + daily carboplatin (25 mg/m2) in the first-line treatment of adults affected by limited small cell lung cancer (SCLC). Patients and Methods: A single-stage phase II design was used; the complete response (CR) rate after chest radiotherapy was the primary end-point. Twenty-three CRs were required out of 38 patients to consider the treatment worthy of further study. Prophylactic cranial irradiation (PCI) was planned in case of CR. Patients aged ≤ 70 were eligible if they had limited SCLC, a performance status not worse than 2 by the ECOG scale and no prior chemotherapy or radiotherapy. Results: From January 1995 to April 1999, 33 patients were enrolled; the median age was 60 years. All the patients started chemotherapy; 23 patients received chest irradiation and concurrent daily carboplatin; 11 patients also received PCI. Toxicity was generally mild. Sixteen CRs (48.5%, 95% CI: 30.8-66.5) were recorded; the objective response rate was 72.7% (95% CI: 54.5-86.7). The median time-to-progression was 7.9 months (95% CI: 6.5-10.4). The median-survival was 10.7 months (95% CI: 9.2-16.1). Conclusion: Induction chemotherapy with carboplatin + epirubicin + VP - 16 followed by chest irradiation plus concurrent daily carboplatin is well-tolerated but not sufficiently active to warrant further study in the treatment of patients with limited SCLC.

Original languageEnglish
Pages (from-to)4179-4183
Number of pages5
JournalAnticancer Research
Volume21
Issue number6 A
Publication statusPublished - 2001

Keywords

  • Chemo-radiotherapy
  • Limited small cell lung cancer
  • Radiosensitizing carboplatin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Carboplatin + epirubicin + VP-16 + lenograstim followed by radiotherapy + carboplatin as radiosensitizer in limited small cell lung cancer. A multicenter phase II study'. Together they form a unique fingerprint.

  • Cite this

    Gridelli, C., Curcio, C., Iaffaioli, R. V., Brancaccio, L., D'Aprile, M., Gebbia, V., Rossi, A., Tortoriello, A., Veltri, E., Maione, P., Barbarisi, A., Gallo, C., Guida, C., & Perrone, F. (2001). Carboplatin + epirubicin + VP-16 + lenograstim followed by radiotherapy + carboplatin as radiosensitizer in limited small cell lung cancer. A multicenter phase II study. Anticancer Research, 21(6 A), 4179-4183.